Literature DB >> 15909996

Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.

Amanda J Mishizen-Eberz1, Erin H Norris, Benoit I Giasson, Roberto Hodara, Harry Ischiropoulos, Virginia M-Y Lee, John Q Trojanowski, David R Lynch.   

Abstract

Alpha-synuclein (alpha-syn) is a major protein component of the neuropathological hallmarks of Parkinson's disease and related neurodegenerative disorders termed synucleinopathies. Neither the mechanism of alpha-syn fibrillization nor the degradative process for alpha-syn has been elucidated. Previously, we showed that wild-type, mutated, and fibrillar alpha-syn proteins are substrates of calpain I in vitro. In this study, we demonstrate that calpain-mediated cleavage near and within the middle region of soluble alpha-syn with/without tyrosine nitration and oxidation generates fragments that are unable to self-fibrillize. More importantly, these fragments prevent full-length alpha-syn from fibrillizing. Calpain-mediated cleavage of alpha-syn fibrils composed of wild-type or nitrated alpha-syn generate C-terminally truncated fragments that retain their fibrillar structure and induce soluble full-length alpha-syn to co-assemble. Therefore, calpain-cleaved soluble alpha-syn inhibits fibrillization, whereas calpain-cleaved fibrillar alpha-syn promotes further co-assembly. These results provide insight into possible disease mechanisms underlying synucleinopathies since the formation of alpha-syn fibrils could be causally linked to the onset/progression of these disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15909996     DOI: 10.1021/bi047846q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  48 in total

1.  Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration.

Authors:  N M Kanaan; J H Kordower; T J Collier
Journal:  Eur J Neurosci       Date:  2008-06       Impact factor: 3.386

2.  Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Authors:  Zachary A Sorrentino; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Kevin H Strang; Jason Caldwell; Benoit I Giasson
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

3.  Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.

Authors:  Silke Nuber; Daniel Tadros; Jerel Fields; Cassia Rose Overk; Benjamin Ettle; Kori Kosberg; Michael Mante; Edward Rockenstein; Margarita Trejo; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-08       Impact factor: 17.088

4.  Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology.

Authors:  Karen A Lewis; Yang Su; Olina Jou; Caroline Ritchie; Chan Foong; Linda S Hynan; Charles L White; Philip J Thomas; Kimmo J Hatanpaa
Journal:  Am J Pathol       Date:  2010-11-05       Impact factor: 4.307

Review 5.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

6.  Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons.

Authors:  João Paulo L Daher; Mingyao Ying; Rebecca Banerjee; Rebecca S McDonald; Myriam Dumas Hahn; Lichuan Yang; M Flint Beal; Bobby Thomas; Valina L Dawson; Ted M Dawson; Darren J Moore
Journal:  Mol Neurodegener       Date:  2009-07-24       Impact factor: 14.195

7.  The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein.

Authors:  Jihoon Kim; Ryuichi Harada; Masaki Kobayashi; Natsuki Kobayashi; Koji Sode
Journal:  Mol Neurodegener       Date:  2010-05-20       Impact factor: 14.195

Review 8.  Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.

Authors:  Sang Myun Park; Kwang Soo Kim
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

9.  Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

Authors:  Dora Games; Peter Seubert; Edward Rockenstein; Christina Patrick; Margarita Trejo; Kiren Ubhi; Benjamin Ettle; Majid Ghassemiam; Robin Barbour; Dale Schenk; Silke Nuber; Eliezer Masliah
Journal:  Am J Pathol       Date:  2013-01-09       Impact factor: 4.307

10.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.